HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Instavit Spray, KeVita Flavors: Health And Wellness New Products Roundup

This article was originally published in The Rose Sheet

Executive Summary

VitaC-LD from Sovereign labs; Instavit at Vitamin Shoppe; Kevita's new flavors; and more news in brief.

You may also be interested in...



Skin Care Line First For New Chapter Founder Schulick, Nutraceuticals In 2020

New Chapter founder Paul Schulick will introduce skin masks, cleansers and lotions with Algatech's topical astaxanthin to maintain skin microbiome. He also plans to launch nutraceuticals once a non-compete agreement with P&G, the owner of his former firm New Chapter, expires in 2020.

UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026

Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108518

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel